A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY OF INEBILIZUMAB IN PARTICIPANTS WITH AUTOIMMUNE HEPATITIS

Registry ID

20240237

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

AMGEN CANADA INC

Last update

2025-12-02

Conditions

• AUTOIMMUNE HEPATITIS

Related clinical trials

• A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF STEROID SPARING STRATEGY IN IMMUNE RELATED HEPATITIS
• BELIMUMAB IN THE MANAGEMENT OF AUTOIMMUNE HEPATITIS: A MULTI-CENTRE, OPEN-LABEL TRIAL OF ADD-ON BELIMUMAB THERAPY TO STANDARD OF CARE

View on source registry